DSM-Firmenich AG DSFIR.AS
Composite 50/100; the shares have moved about 34% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Quality ranks 33/100 — a moderate mark against it.
Momentum ranks 82/100 — a strong point in its favour. Income ranks 69/100 — a moderate point in its favour. Balance-sheet strength ranks 53/100 — a slight point in its favour.
Quality ranks 33/100 — a moderate mark against it. Growth ranks 41/100 — a slight mark against it. Valuation ranks 45/100 — a slight mark against it.
What the company does DSM-Firmenich AG develops nutrition, health, and beauty solutions across Perfumery & Beauty, Taste, Texture & Health, and Health, Nutrition & Care segments, leveraging natural, synthetic, and biotech ingredients.
Key financials Revenue grew 3% while EPS surged 1121%, yet margins remain weak: gross 39%, operating 7%, and net -12%. ROE is 2%, ROA 1%, and ROCE 3%. Debt/equity is 0.29 with net debt/EBITDA at 2.35.
Stock health Quality score is poor at 22, but growth (66) and momentum (72) are strong. The stock is up 36% over 3 months and 31% over 6 months, with RSI at 55.10. Dividend yield is 3%, though payout ratio is 207%.
Price vs fair value The stock trades at a **PREMIUM of 55.80%** to our fair-value estimate and a **discount of 2.25%** to the analyst 12-month target. - Fair-value premium of 55.80% reflects weak profitability (net margin -12%) despite high forward P/E of 23.31 (Valuation 59.4). - Discount to target may stem from strong momentum (72.4) and growth score (65.6). - Poor quality score (22.0) and negative FCF yield (-0.1%) limit upside despite PEG of 0.12.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-04, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.